If you’ve ever experienced sticker shock at the pharmacy, you’re not alone in realizing that our healthcare system often fails to prioritize patients. The reality is that other countries and corporations benefit at your expense.
In most aspects of life, you’re aware of costs upfront. At restaurants, menus provide clear options and pricing, allowing you to make informed choices. The healthcare sector, however, offers a different experience—often characterized by unexpected charges. This lack of transparency has contributed to decades of escalating healthcare costs, leaving a third of working-age adults burdened with medical debt.
Despite allocating $5.5 trillion of GDP to healthcare expenditure, it’s astonishing that patients’ needs are still unmet. To combat this exploitation, President Trump initiated TrumpRx as part of his Great Healthcare Plan. This initiative aims to empower patients with greater control over their healthcare expenses, curbing the freeloading by international entities. Through TrumpRx, Americans can access medications directly from manufacturers, bypassing insurance disputes and eliminating surprise costs at the pharmacy. This approach ensures that taxpayer-funded medications don’t end up in Europe at drastically reduced prices, providing a straightforward way to obtain prescriptions without intermediaries.
Consider a patient managing rheumatoid arthritis. These medications can be complex, with generic alternatives not always providing the same effectiveness. Despite coverage on paper, patients often face hurdles like extensive prior authorizations or “fail first” policies, where preferred alternatives by healthcare plans may not suit the individual’s needs. TrumpRx addresses this by offering comprehensive access to necessary medications, ensuring affordability and availability for patients as prescribed by their doctors. Research from the America First Policy Institute indicates that patients using drugs priced under TrumpRx’s “Most Favored Nation” model could see their annual healthcare expenses reduced by as much as 95 percent.
This initiative reflects the kind of practical problem-solving that’s akin to balancing a household budget. By challenging systemic freeloading, President Trump advocates for individuals, like a single mom navigating Obamacare. Even if her medication is covered by insurance, a cost-benefit analysis suggests she might save up to 38.5 percent by opting for TrumpRx over her current plan. This initiative liberates her from a healthcare system that doesn’t always serve her interests.
This patient-centric policy from President Trump aims to simplify healthcare, granting patients more control and reducing costs. By swiftly addressing the freeloading issue, he has tackled the rising prices and lack of transparency that have long plagued patients.
For decades, other countries invested little in developing cures because they could just pay pennies on the dollar for the treatments developed in the American market. America-last policymakers were so desperate to seek the approval of other countries that they let American patients get ripped off. Instead of insisting that other countries pay their fair share for drugs that American companies and American research institutions developed, they green lit trade deals that allowed other countries to charge much less, or, allowed countries to access generic versions of American taxpayer-funded drugs before Americans could access the generic version of those drugs.
TrumpRx uses Most Favored Nation pricing to end this global freeloading, and it is already working. Reports show that costs between Switzerland and the United States are starting to even out. In addition, the Trump administration has secured a commitment from the U.K. to end their share in global freeloading. From defense to health care, American taxpayers aren’t going to let other wealthy countries freeload off of our investments.
It’s not just wealthy countries that freeload off American patients – it’s Fortune 50 companies that use anti-competitive practices to siphon patient dollars away from patient care. President Trump ended this freeloading by signing into law a long-awaited PBM transparency bill, which forces PBMs to provide an itemized receipt for their drug costs, meaning no more hidden costs. The administration, through the Federal Trade Commission, announced a settlement with one of the largest PBMs, Express Scripts, to reverse decades of anti-competitive behavior which led to patients being forced into higher-cost drugs. And now through TrumpRx, the president is making drugs available to all Americans at a no-middleman cost – making these PBMs compete with TrumpRx to provide drugs at the lowest cost.
President Trump is putting patients first by giving Americans more control over their health and their healthcare dollars by ending the freeloading off of the American patient.
Hannah Anderson is the Director of Healthy America Policy and Senior Director of Policy at the America First Policy Institute.
